Company Information

  

Address: 4545 TOWNE CENTRE COURT  
City: SAN DIEGO 
State: CA 
Zip Code: 92121 
Telephone: (858) 255-5959 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biotechnology company focused on precision medicine in oncology. Our goal is not just to shrink tumors, but to eradicate residual disease - the source of cancer relapse and recurrence - in precisely defined patient populations. We are pursuing an integrated therapeutic, or Rx, and companion diagnostic, or Dx, strategy for treating cancer patients. Our Rx efforts are focused on in-licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Our Dx efforts aim to pair these product candidates with biomarker-based companion diagnostics that are designed to precisely identify, at the molecular level, the patients who are most likely to benefit from the therapies we develop.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-2.63NAN/E
06/2017-2.70NAN/E
03/2017-2.86NAN/E
12/2016-2.69NAN/E
09/2016-3.44NAN/E
06/2016-3.34NAN/E
03/2016-3.08NAN/E
12/2015-3.44NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.30Total Liab/Total Assets0.35
Net Inc/Total Assets-0.72Total Liab/Inv Cap0.39
Net Inc/Inv Cap-0.81Total Liab/Comm Equity0.14
Pretax Inc/Net SalesNAInterest Coverage Ratio-31.25
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/Equity0.31
SG&A/NetSalesNATotal Debt/Equity0.31
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio6.39
Inventory TurnoverNACurrent Ratio6.39
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) NA NA NA 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 6.54 5.50 5.57 6.89
Operating Income -28.21 -27.67 -39.62 -27.39
Interest Exp 0.85 0.83 0.81 0.81
Pretax Income -28.60 -28.28 -40.16 -28.21
Other Income 0.46 0.22 0.27 -0.01
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -28.60 -28.28 -40.16 -28.21

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 144.81 165.38 103.99 107.98
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 148.67 169.34 107.96 111.85
Net Property, Plant & Equipment 4.38 4.68 5.50 6.27
Total Assets 154.37 179.53 119.15 144.91
Liabilities        
Accounts Payable 20.69 19.48 21.02 17.52
Debt in Current Liabilities NA NA NA 0.00
Total Current Liabilities 24.50 23.19 21.02 17.52
Long-Term Debt 29.99 29.84 29.68 29.52
Total Liabilities 66.35 64.65 61.17 50.14
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.00 0.00
Retained Earnings -348.70 -320.10 -291.82 -251.66
Treasury Stock NA NA NA NA
Total Stockholders' Equity 88.01 114.88 57.98 94.77
Total Liabilities and Stockholders' Equity 154.37 179.53 119.15 144.91

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -24.74 -21.37 -26.18 -18.69
Net Cash Provided by Investing Activities -7.01 -32.94 33.10 19.59
Net Cash Provided by Financing Activities 0.16 82.83 1.37 -0.04

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.01-0.05--
12/20130.00-14.21--
12/20140.15-39.99-2.18
12/20150.00-92.46-3.44
12/20160.00-103.64-2.69
Growth Rates-100.00----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1713548,33972.87




Report Date : 12/4/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.